Table 1.
Clinical summaries and serum/CSF samples tested from patients with definite NMDAR-antibody encephalitis and disease controls
| Number of patients | Number of serum samples (first available sample median days from episode onset, range) | Number of CSF samples (first available sample median days from episode onset, range) | Median age (range), years, at disease onset (or time of sampling, for controls) | Female (%) | OT detected (%) | |
|---|---|---|---|---|---|---|
| Cases | ||||||
| Definite NMDAR-antibody encephalitisa | 108 | 285 (26, 0–3029) | 60 (27, 0–579) | 20.5 (1–74) | 78 (72%) | 29 (27%b) |
| Controls | ||||||
| Healthy volunteers | 55 | 55 | N/A | 36 (20–71) | 64 | N/A |
| Traumatic brain injury | 58 | 58 | 31 | 39 (21–72) | 23 | N/A |
| Bipolar disorder | 222 | 395 | N/A | 44 (18–62) | 54 | N/A |
| Total controls | 335 | 508 | 31 | 43 (18–72) | 50 | N/A |
N/A = not available.
a
All patients had NR1-IgG autoantibodies detectable in CSF and a compatible clinical syndrome.
b
No tumours were documented in the male cases.